Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial

Background Glioblastoma (GBM) patients have poor survival outcomes despite treatment advances and most recurrences occur within the radiation field. Survival outcomes after dose escalation through hypofractionated accelerated RT(HART) were evaluated in this study. We previously reported the study’s initial results showing similar survival outcomes with acceptable toxicities. Updated results after 5 years are being analysed to determine long-term survival trends. Patients and methods 89 patients of newly diagnosed GBM after surgery were randomized to conventional radiotherapy (CRT) or HART. CRT arm received adjuvant RT 60 Gy in 30 fractions over 6 weeks and the HART arm received 60 Gy in 20 fractions over 4 weeks, both with concurrent and adjuvant temozolomide. Results 83 patients were eligible for analysis. After a median follow-up of 18.9 months, the median OS was 26.5 months and 22.4 months in the HART and CRT arms respectively. 5 year OS was 18.4% in the HART arm versus 3.8% in the CRT arm. This numerical difference in overall survival between the two arms was not statistically significant. The median PFS was not significantly different. Conclusion The long-term results of the trial support HART as a promising treatment option with comparable survival outcomes to the current standard of care. Phase III trials are required for further validation of this regimen which has the potential to become the new standard of care in GBM..

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:164

Enthalten in:

Journal of neuro-oncology - 164(2023), 1 vom: 15. Juli, Seite 141-146

Sprache:

Englisch

Beteiligte Personen:

Mallick, Supriya [VerfasserIn]
Gupta, Subhash [VerfasserIn]
Amariyil, Adila [VerfasserIn]
Kunhiparambath, Haresh [VerfasserIn]
Laviraj, M. A. [VerfasserIn]
Sharma, Seema [VerfasserIn]
Sagiraju, Hari Krishna Raju [VerfasserIn]
Julka, Pramod Kumar [VerfasserIn]
Sharma, Dayanand [VerfasserIn]
Rath, Goura Kishor [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Accelerated radiotherapy
Glioblastoma
Hypo-fractionated radiotherapy
Surgery
Temozolomide

Anmerkungen:

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s11060-023-04391-7

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2145264922

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?